Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
J Natl Compr Canc Netw. 2010 Mar;8(3):347-52. doi: 10.6004/jnccn.2010.0023.
A significant amount of literature is available on treatment monitoring and response assessment in lymphoma using FDG-PET, yet confusion exists concerning the potential and limitations of FDG-PET for determining the presence of residual disease during chemotherapy (interim FDG-PET). This article reviews the role of interim FDG-PET in 3 important scenarios: untreated diffuse large B-cell lymphoma, untreated Hodgkin lymphoma, and relapsed or refractory aggressive lymphoma in transplant-eligible patients, and provides recommendations on the use of this imaging modality in these settings.
有大量文献可用于使用 FDG-PET 监测淋巴瘤的治疗和反应评估，但对于 FDG-PET 在确定化疗期间（中期 FDG-PET）残留疾病方面的潜力和局限性仍存在混淆。本文回顾了中期 FDG-PET 在 3 种重要情况下的作用：未经治疗的弥漫性大 B 细胞淋巴瘤、未经治疗的霍奇金淋巴瘤以及适合移植的复发或难治性侵袭性淋巴瘤，并就该影像学模式在这些情况下的应用提供了建议。
